Editorial: Challenges faced by the global polio eradication initiative

Expert Review of Vaccines

Volumn 9, Issue 5, 2010, Pages 447-449

  Wassilak, Steven ^a   Orenstein, Walter ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

DISEASE SURVEILLANCE; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION CONTROL; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; DISEASE TRANSMISSION; EPIDEMIC; IMMUNOLOGY; TREATMENT FAILURE; VACCINATION;

DISEASE OUTBREAKS; HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINES; TREATMENT FAILURE; VACCINATION;

EID: 77952199776     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.45     Document Type: Editorial

References (17)

1. Centers for Disease Control and Prevention. Progress toward interruption of wild poliovirus transmission - worldwide, 2008. Morb. Mort. Wkly Rep. 58(12), 308-312 (2009).
2. Arita I, Nakane M, Fenner F. Public health. Is polio eradication realistic? Science 312(5775), 852-854 (2006).
3. Caplan AL. Is disease eradication ethical? Lancet 373(9682), 2192-2193 (2009).
4. Cochi SL, Kew O. Polio today: are we on the verge of global eradication? J. Am. Med. Assoc. 300(7), 839-841 (2008).
5. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Vaccines (Fifth Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA, 631-685 (2008).
6. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann. Rev. Microbiol. 59, 587-635 (2005).
7. Thompson KM, Tebbens RJ, Pallansch MA et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am. J. Public Health 98(7), 1322-1330 (2008).
8. Grassly NC, Wenger J, Durrani S et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 369(9570), 1356-1362 (2007). (Pubitemid 46613904)
9. el-Sayed N, el-Gamal Y, Abbassy AA et al. Monovalent type 1 oral poliovirus vaccine in newborns. N. Engl. J. Med. 359(16), 1655-1665 (2008).
10. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13(5), 926-939 (1991).
11. Caceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin. Infect. Dis. 33(4), 531-541 (2001).
12. World Health Organization. Advisory Committee on Poliomyelitis Eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Weekly Epidemiol. Rec. 84(29), 289-290 (2009).
13. Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation - 21 countries, 2002-2005. Morb. Mort. Wkly Rep. 55(6), 145-150 (2006).
14. Centers for Disease Control and Prevention. Wild poliovirus type 1 and type 3 importations - 15 countries, Africa, 2008-2009. Morb. Mort. Wkly Rep. 58(14), 357-362 (2009).
15. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication - Nigeria, January 2008 - July 2009. Morb. Mort. Wkly Rep. 58(41), 1150-1154 (2009).
16. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication - Afghanistan and Pakistan, 2009. Morb. Mort. Wkly Rep. 59(09), 268-272 (2010).
17. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication - India, January 2007-May 2009. Morb. Mort. Wkly Rep., 58(26), 719-723 (2009).